10-Q: Xeris Biopharma Reports Q1 2024 Results: Revenue Growth Driven by Recorlev, Debt Refinancing Completed

Xeris Biopharma's first quarter of 2024 saw a revenue increase driven by Recorlev sales, alongside a debt refinancing to extend maturities.

Summary

• Xeris Biopharma reported a net loss of $18.98 million for the first quarter of 2024, compared to a net loss of $16.83 million in the same period last year.
• Product revenue increased to $40.26 million, up from $32.26 million in Q1 2023, with Recorlev sales showing the most significant growth.
• Total revenue for the quarter was $40.64 million, compared to $33.20 million in the first quarter of 2023.
• The company completed a debt refinancing, securing $200 million in term loans and an additional $15.2 million for the potential redemption of 2025 convertible notes.
• Research and development expenses increased to $7.82 million, up from $4.84 million in Q1 2023, due to investments in pipeline programs.
• Selling, general, and administrative expenses also increased to $38.38 million, up from $33.61 million in Q1 2023, due to higher personnel costs and rent expenses.
• The company's cash and cash equivalents were $62.69 million as of March 31, 2024, down from $67.45 million at the end of 2023.
• The company believes its current cash resources are sufficient to sustain operations for at least the next 12 months.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth, particularly in Recorlev, the company is still operating at a loss and has increased expenses. The debt refinancing is a positive step, but the need for future financing remains a concern. Overall, the sentiment is cautiously optimistic.

Positives

• The company experienced strong revenue growth, particularly in Recorlev sales.
• The debt refinancing extends maturities and provides additional capital.
• The company has a robust patent portfolio, including key patents for its commercial products.
• The company believes its current cash resources are sufficient to sustain operations for at least the next 12 months.

Negatives

• The company reported a net loss of $18.98 million for the quarter.
• Operating expenses, including research and development and selling, general, and administrative costs, increased year-over-year.
• Cash and cash equivalents decreased from the end of 2023.

Risks

• The company has incurred operating losses since inception and expects to continue to incur net losses for at least the next 12 months.
• The company's ability to fund operations depends on the amount and timing of cash received from product revenue and potential future financings.
• Market volatility and macroeconomic factors could adversely impact the company's ability to access capital.
• The company is subject to risks similar to other specialty pharmaceutical companies, including successful commercialization and market acceptance of available products and any future products, if and when approved, successful development of product candidates, the development of new technological innovations by competitors, and protection of intellectual property.

Future Outlook

The company expects to continue to incur net losses for at least the next 12 months and will continue to seek public equity and debt financing to meet its capital requirements. The company believes its current cash resources are sufficient to sustain operations for at least the next 12 months.

Management Comments

• Our goal is to build an innovative, self-sustaining, growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing clinically meaningful products across a range of therapies.
• We are focused on executing against the opportunities made possible by Gvoke, Recorlev, and Keveyis in order to maintain our momentum of growth and enable the financial self-sufficiency of our Company.
• We believe these three distinct pillars of our strategy can bring new products to market and transform the lives of patients with life-impacting diseases and ultimately drive value for Xeris shareholders.

Industry Context

The company's focus on endocrinology and rare diseases aligns with the growing demand for specialized treatments in these areas. The company's proprietary formulation science also positions it to develop new and innovative products and partnerships.

Comparison to Industry Standards

• Xeris's revenue growth, particularly in Recorlev, is notable compared to other companies in the rare disease space, such as Ultragenyx Pharmaceutical Inc. and BioMarin Pharmaceutical Inc., which also focus on niche markets.
• The company's debt refinancing is a common strategy for biotech companies to manage their capital structure, similar to actions taken by companies like Amicus Therapeutics and Sarepta Therapeutics.
• The increase in R&D spending is consistent with the industry trend of investing in pipeline development, as seen in companies like Vertex Pharmaceuticals and Alnylam Pharmaceuticals.
• The company's cash burn rate is comparable to other biotech companies in the commercialization phase, such as Acadia Pharmaceuticals and Global Blood Therapeutics.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses but encouraged by the revenue growth and debt refinancing.
• Employees may be affected by the company's financial performance and future funding needs.
• Customers may benefit from the company's continued focus on developing and commercializing new products.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to focus on commercial execution of its products.
• The company will continue to leverage its proprietary formulation science to develop new product candidates.
• The company will collaborate with pharmaceutical and biotechnology companies to apply its formulation science to enhance their products.

Key Dates

Keywords

Xeris Biopharma, Gvoke, Recorlev, Keveyis, revenue, debt refinancing, pharmaceutical, biopharmaceutical, hypoglycemia, Cushings syndrome, periodic paralysis